Answers are grounded in this paper and cite their sources.
Reveals high subcutaneous and poor oral meloxicam bioavailability in white storks, indicating subcutaneous injection is an effective alternative to intramuscular dosing.
Background Meloxicam (MLX) is a preferential cyclooxygenase-2 inhibitor widely used in avian medicine as an anti-inflammatory agent. Despite marked interspecific variability in avian drug disposition, no pharmacokinetic data are available for MLX in the white stork ( Ciconia ciconia ). This study aimed to characterise and compare the plasma pharmacokinetics of MLX in this species. Methods Six clinically stable, non-releasable white storks (three of each sex) received a single 1 mg/kg dose of MLX by the IM, SC and PO routes in a randomised three-way crossover design with a 2-week washout period between treatments. Plasma MLX concentrations were quantified up to 24 h using HPLC and analysed using non-compartmental methods. Results Peak plasma concentrations (C max ) differed significantly among all three routes (IM 11.49 ± 2.34, SC 6.43 ± 1.62, PO 1.53 ± 0.89 µg/mL; p < 0.05) and were reached most rapidly after IM administration. Systemic exposure was comparable between the IM and SC routes (AUC 0–24h 80.7 ± 40.2 and 81.1 ± 22.7 µg·h/mL, respectively) and approximately 7-fold greater than after PO administration (11.9 ± 4.8 µg·h/mL; p < 0.05), corresponding to relative bioavailabilities versus IM of 100.4% for SC and 14.8% for PO. Terminal half-life progressively increased from IM (9.81 ± 2.30 h) through SC (15.13 ± 4.41 h) to PO (18.85 ± 2.16 h). Conclusion SC administration may represent a practical parenteral alternative to IM, whereas PO administration displayed low and variable bioavailability in white storks.
No takes yet. Share an insight, caveat, or question.
Gunes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: